French biotech Ipsen to buy Memo Therapeutics for $230 million upfront
01/07/2026 06:17
French biotech Ipsen to buy Memo Therapeutics for $230 million upfront July 1 (Reuters) - French biotech company Ipsen IPN.PA will buy Switzerland-based Memo Therapeutics to add potravitug, a Phase II clinical-stage antibody targeting BK polyomavirus, to its portfolio, the company said on Wednesday.
The deal is valued at €200 million ($228.16 million) upfront, with the potential to exceed €700 million through additional milestone payments, and is expected to close in the third quarter of 2026.
($1 = 0.8766 euros)
(Reporting by Lucie Barbier)
((Email: lucie.barbier@thomsonreuters.com))
Recent news on Ipsen SA
See all newsHealth Rounds: New blood test matches gold standard for liver disease diagnosis
Brief: Ipsen Late-Breaking Data Raises Ambitions In PBC
Brief: Charles River Laboratories International Virtual Control Group To Be Used In Glp Study For Ipsen
Pharming shares rise after preliminary Q3 revenue beat
France's Ipsen Q3 sales rise 28% driven by core portfolio